725 related articles for article (PubMed ID: 10190381)
1. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
Wong W; Liu P; Blendis L; Wong F
Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
[TBL] [Abstract][Full Text] [Related]
2. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.
Gerbes AL; Gülberg V; Waggershauser T; Holl J; Reiser M
Hepatology; 1998 Sep; 28(3):683-8. PubMed ID: 9731559
[TBL] [Abstract][Full Text] [Related]
3. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
4. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
5. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
6. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.
Ochs A; Rössle M; Haag K; Hauenstein KH; Deibert P; Siegerstetter V; Huonker M; Langer M; Blum HE
N Engl J Med; 1995 May; 332(18):1192-7. PubMed ID: 7700312
[TBL] [Abstract][Full Text] [Related]
7. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.
Quiroga J; Sangro B; Núñez M; Bilbao I; Longo J; García-Villarreal L; Zozaya JM; Betés M; Herrero JI; Prieto J
Hepatology; 1995 Apr; 21(4):986-94. PubMed ID: 7705810
[TBL] [Abstract][Full Text] [Related]
8. Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites.
Wong F; Bomzon A; Allard J; Liu P; Blendis L
Clin Sci (Lond); 1999 May; 96(5):467-74. PubMed ID: 10209078
[TBL] [Abstract][Full Text] [Related]
9. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
Rössle M; Ochs A; Gülberg V; Siegerstetter V; Holl J; Deibert P; Olschewski M; Reiser M; Gerbes AL
N Engl J Med; 2000 Jun; 342(23):1701-7. PubMed ID: 10841872
[TBL] [Abstract][Full Text] [Related]
10. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
Somberg KA; Lake JR; Tomlanovich SJ; LaBerge JM; Feldstein V; Bass NM
Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
[TBL] [Abstract][Full Text] [Related]
11. [Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites in 21 patients].
Vandistel G; Nevens F; Stockx L; Raat H; Wilms G; Fevery J
Ned Tijdschr Geneeskd; 1996 Dec; 140(49):2455-8. PubMed ID: 8999346
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites.
Wong F; Sniderman K; Liu P; Allidina Y; Sherman M; Blendis L
Ann Intern Med; 1995 Jun; 122(11):816-22. PubMed ID: 7741365
[TBL] [Abstract][Full Text] [Related]
13. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation.
Wong F; Tobe S; Legault L; Logan AG; Skorecki K; Blendis LM
Hepatology; 1993 Sep; 18(3):519-28. PubMed ID: 8395457
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
Tan HK; James PD; Sniderman KW; Wong F
J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites.
Martinet JP; Legault L; Cernacek P; Roy L; Dufresne MP; Spahr L; Fenyves D; Pomier-Layrargues G
J Hepatol; 1996 Nov; 25(5):700-6. PubMed ID: 8938548
[TBL] [Abstract][Full Text] [Related]
16. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
[TBL] [Abstract][Full Text] [Related]
17. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
[TBL] [Abstract][Full Text] [Related]
18. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
Membreno F; Baez AL; Pandula R; Walser E; Lau DT
J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
[TBL] [Abstract][Full Text] [Related]
19. Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites.
Nair S; Singh R; Yoselewitz M
J Vasc Interv Radiol; 2004 Dec; 15(12):1431-4. PubMed ID: 15590801
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score.
Trotter JF; Suhocki PV; Rockey DC
Am J Gastroenterol; 1998 Oct; 93(10):1891-4. PubMed ID: 9772050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
